Article

Beyond IC <sub>50</sub> - A computational dynamic model of drug resistance in enzyme inhibition treatment

2024-03-26

Abstract excerpt

Resistance to therapy is a major clinical obstacle to treatment of cancer and communicable diseases. Chronic myeloid leukaemia (CML) is a blood cancer that is treated with Abl1 inhibitors, and is often seen as a model for targeted therapy and drug resistance. Resistance to the first-line treatment occurs in approximately one in four patients. The most common cause of resistance is mutations in the Abl1 enzyme. Dif...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7be2c6a6-af8c-5781-a706-e86495cbf517
DOI: 10.1101/2024.03.21.586067

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Beyond IC <sub>50</sub> - A computational dynamic model of drug resistance in enzyme inhibition treatmentDOI 10.1101/2024.03.21.586067Read

Beyond IC50-A computational dynamic model of drug resistance in enzyme inhibition treatment.Semantic proximity Read

Drug resistance in cancer: Principles of emergence and preventionSemantic proximity Read

Mutation in Abl kinase with altered drug binding kinetics indicates a novel mechanism of imatinib resistanceSemantic proximity Read

A combined computational and experimental strategy identifies mutations conferring resistance to drugs targeting the BCR-ABL fusion protein.Semantic proximity Read

A general framework for inhibitor resistance in protein kinases.Semantic proximity Read

Drug resistance in cancer mechanisms and modelsSemantic proximity Read

Interplay of mutations, alternate mechanisms, and treatment breaks in leukaemia: Understanding and implications studied with stochastic models.Semantic proximity Read

Profiling of the drug resistance of thousands of Src tyrosine kinase mutants uncovers a regulatory network that couples autoinhibition to catalytic domain dynamicsSemantic proximity Read

Biochemical Mechanisms of Resistance to Small-Molecule Protein Kinase InhibitorsSemantic proximity Read

Cumulative mechanism of several major imatinib-resistant mutations in Abl kinaseSemantic proximity Read

Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance.Semantic proximity Read

How to get rid of inhibitors.Semantic proximity Read